Biogen Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Biogen Inc 公司

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Biogen Inc简介



公司代码BIIB

公司名称Biogen Inc

上市日期Sep 17, 1991

CEOViehbacher (Christopher A)

员工数量7605

证券类型Ordinary Share

年结日Sep 17

公司地址225 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话17814642000

网址https://www.biogen.com/

公司代码BIIB

上市日期Sep 17, 1991

CEOViehbacher (Christopher A)

Biogen Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

Mr. Jesus B. Mantas

Independent Director

8.42K

+28.15%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.04K

+12.73%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

5.88K

+59.46%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+43.29%

名称

名称/职务

职务

持股

持股变动

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

收入明细

单位: USD更新时间: 4月6日周一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

其他

3.25B

32.82%

地区USD

名称

营收

占比

United States

3.73B

37.67%

Rest of world

3.57B

36.11%

United states-Revenues from anti-CD20 therapeutic

1.86B

18.81%

Rest of World-Other revenues

732.90M

7.41%

业务

地区

业务USD

名称

营收

占比

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

其他

3.25B

32.82%

股东统计

更新时间: 15 小时前

持股股东

股东类型

持股股东

占比

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

其他

67.39%

持股股东

占比

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

其他

67.39%

股东类型

持股股东

占比

Investment Advisor

66.96%

Investment Advisor/Hedge Fund

25.97%

Hedge Fund

6.52%

Pension Fund

3.17%

Research Firm

2.81%

Sovereign Wealth Fund

1.84%

Bank and Trust

1.76%

Individual Investor

0.20%

Family Office

0.16%

机构持股



更新时间: 4月9日周四

报告期

机构数

持股数

持股占比

持股变动

2026Q1

2085

144.76M

98.05%

-3.98M

2025Q4

1994

139.65M

97.81%

+140.37K

2025Q3

2054

139.52M

98.56%

+3.73M

2025Q2

2076

135.78M

99.30%

-133.40K

2025Q1

2125

136.05M

101.20%

-12.08M

2024Q4

2114

138.28M

98.83%

+2.02M

2024Q3

2089

135.94M

98.13%

+100.43K

2024Q2

2100

135.44M

97.85%

-355.51K

2024Q1

2106

135.99M

97.60%

-5.88M

2023Q4

2136

135.17M

94.89%

+4.09M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

PRIMECAP Management Company

14.76M

10.06%

-196.70K

-1.32%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

8.73M

5.95%

+513.30K

+6.25%

Dec 31, 2025

Fidelity Management & Research Company LLC

7.97M

5.43%

+6.90M

+642.96%

Dec 31, 2025

State Street Investment Management (US)

7.16M

4.88%

-160.73K

-2.20%

Dec 31, 2025

Geode Capital Management, L.L.C.

4.20M

2.86%

+130.62K

+3.21%

Dec 31, 2025

Wellington Management Company, LLP

3.55M

2.42%

-695.24K

-16.37%

Dec 31, 2025

Point72 Asset Management, L.P.

2.81M

1.92%

-1.06M

-27.36%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

2.64M

1.8%

+374.66K

+16.55%

Dec 31, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco Biotechnology & Genome ETF

5.49%

First Trust NASDAQ Pharmaceuticals ETF

4.45%

iShares Neuroscience and Healthcare ETF

4.25%

First Trust NYSE Arca Biotechnology Index Fund

3.53%

VanEck Biotech ETF

3.46%

Invesco Pharmaceuticals ETF

3.01%

iShares Health Innovation Active ETF

2.81%

First Trust Health Care Alphadex Fund

2.4%

ProShares Ultra Nasdaq Biotechnology

2.22%

Alger Russell Innovation ETF

2.21%

Invesco Biotechnology & Genome ETF

占比5.49%

First Trust NASDAQ Pharmaceuticals ETF

占比4.45%

iShares Neuroscience and Healthcare ETF

占比4.25%

First Trust NYSE Arca Biotechnology Index Fund

占比3.53%

VanEck Biotech ETF

占比3.46%

Invesco Pharmaceuticals ETF

占比3.01%

iShares Health Innovation Active ETF

占比2.81%

First Trust Health Care Alphadex Fund

占比2.4%

ProShares Ultra Nasdaq Biotechnology

占比2.22%

Alger Russell Innovation ETF

占比2.21%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据